Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MeiraGTx

- PMLiVE

UK firm Nightstar bags FDA fast-track status for gene therapy

Its choroideremia disease candidate gets RMAT designation

- PMLiVE

UK, Germany back routine use of J&J’s Tremfya

The IL-23 inhibitor is currently being assessed in other EU countries

- PMLiVE

AMICULUM boosts global healthcare communications offering with a new specialist agency, Seques®

AMICULUM is entering its 18th year of growth as an independent healthcare communications and consulting business. Today we are delighted to announce the launch of the first communications agency specializing...

AMICULUM

- PMLiVE

J&J moves quickly ahead with trials of myeloma CAR-T

Expects to start trials during the second half of this year

- PMLiVE

Safety scuppers combo trials with J&J/Genmab’s Darzalex

Studies revealed a “numerical increase” in patient deaths when Darzalex was combined with Roche’s Tecentriq

Biomarin

BioMarin ups the ante for pivotal haemophilia gene therapy trial

Adds another 90 patients to the GENEr8-1 registration study

- PMLiVE

Janssen named ‘Pharma Company of the Year’ at business intelligence awards

Adelphi Research takes home ‘Agency of the year’ trophy

- PMLiVE

FDA clears first-line use for J&J’s Darzalex

Front-line approval a milestone for blockbuster-tipped myeloma drug

- PMLiVE

Morning brief: Herzuma launched in Europe, rare disease status for Orchard candidate and more

A rapid round-up of pharma, biotech and healthcare news

- PMLiVE

J&J pays $140m upfront for cancer-busting virus firm BeneVir

The total value of the deal could go above $1bn if the biotech’s candidates perform well

- PMLiVE

Novartis buys gene therapy firm AveXis for $8.7bn

Lead candidate AVXS-101 could potentially replace regular drug treatment for SMA with a one-off intervention

- PMLiVE

J&J takes option on Theravance’s JAK drug in $1bn deal

TD-1473 has potential treating ulcerative colitis, Crohn’s and IBD patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links